|Bid||159.60 x 100|
|Ask||161.96 x 100|
|Day's Range||160.02 - 160.99|
|52 Week Range||129.82 - 170.00|
|PE Ratio (TTM)||59.71|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||1.88 (1.14%)|
|1y Target Est||174.96|
Kalamazoo, Michigan - March 22, 2018 - Stryker Corporation (NYSE:SYK) announced that it will host a conference call on Thursday, April 26, 2018 at 4:30 p.m., Eastern Time, to discuss the Company`s operating ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding SYK totaled $2.48 billion.
Haemonetics (HAE) expects its transfusion management business to grow at a compound annual growth rate (or CAGR) in the low to mid teens. Haemonetics has planned to opt for a key account strategy. The company aims to strengthen its worldwide presence by expanding its global sales team and partnering with other software vendors and players in this segment, like Helmer.
Kalamazoo, Michigan - March 21, 2018 - Stryker Corporation (NYSE:SYK) announced that its 2018 Annual Meeting of Shareholders is scheduled as follows: May 2, 2018 - 2:00 p.m. Eastern Time Radisson Plaza ...
Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18. Although the combination of the NexSys PCS device and the NexLynk software is designed to result in a completely integrated and optimal bidirectional system, NexSys PCS supports an open architecture and can work with any other donor management software (or DMS). NexLynk software, however, has been designed to work optimally with NexSys PCS, and it thus eliminates the need for the translation of data between the device and the software.
In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise. The company has earned ~48.4% of its total revenue from its plasma franchise YTD (year-to-date) in fiscal 2018. Approximately 91% of the plasma segment’s total revenue in fiscal 2017 was attributable to the sale of disposables.
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.
On its fiscal 3Q18 earnings conference call, Haemonetics (HAE) increased the guidance for its fiscal 2018 adjusted EPS (earnings per share) by ~$0.12 to the range $1.80–$1.90. Haemonetics has calculated this EPS guidance by assuming a positive impact from its overperformance in fiscal 3Q18 and a negative impact from its anticipated investments in fiscal 4Q18. Excluding the impact of its restructuring and turnaround expenses, the company expects $125 million worth of free cash flow in fiscal 2018.
Haemonetics (HAE) expects to report fiscal 2018 revenue in line with what it witnessed in fiscal 2017. The company also expects to witness 6% YoY revenue growth in its hospital business, lower than its previously projected revenue growth rate range of 7%–10%. Haemonetics, however, expects its blood center business to report a 7% YoY fall in fiscal 2018 revenue, which is at the lower end of its expectation of a fall of 7%–10%.
ConMed (CNMD) expects to witness the positive impact of around 0.5–1.0 percentage points on its fiscal 2018 adjusted gross margin, attributable to various cost-saving initiatives. ConMed has also projected an improvement of ~0.2–0.5 percentage points in its ratio of SG&A (selling, general, and administrative) expenses to total sales for fiscal 2018 on a YoY (year-over-year) basis. ConMed also expects its 2018 R&D (research and development)-to-sales ratio to be at the higher end of the projected range of 4.5%–5%.
ConMed (CNMD) expects to report revenue growth in the range of 5%–6.5% on a reported basis and in the range of 4.0%–5.0% on a CC (constant currency) basis for fiscal 2018. The company has projected a favorable top-line impact of 100–150 basis points, resulting from foreign exchange movements for fiscal 2018. In 2017, ConMed reported a ~4.3% YoY (year-over-year) rise in revenues on a CC basis, which would be in line with the average revenue growth in the medical technology industry.
Headquartered in Utica, New York, ConMed (CNMD) currently employs 3,100 people worldwide. In 4Q17, ConMed reported total sales close to $222.6 million, which represents a YoY (year-over-year) rise of ~7.9% on a CC (constant currency) basis and 9% on a reported basis, driven by the robust uptake of its products in the US and in international geographies. For fiscal 2017, ConMed reported total sales close to $796 million, which represents a YoY rise of ~4.3%, both on a CC and reported basis.
On February 26, 2018, Stryker (SYK) closed trading at $165.77. According to Stryker, it has delivered sales growth consistently higher than that of the average performance of the medical technology industry over the past several years. The stock is currently trading above its 200-day moving average of $160.03 and its 50-day moving average of $160.03.
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
In 4Q17, the momentum in Stryker’s (SYK) Mako robot installations continued with total worldwide installations of 35 Mako robots, of which 27 were in the United States. The trend emphasizes Mako’s expansion in new and underpenetrated markets. Since Mako’s launch, Stryker has been focused on training an increasing number of surgeons on its total knee application, which should help increase its utilization rate.